Uncovering Mechanisms of Lung Cancer Resistance to Common Therapy

Researchers have identified nongenetic mechanisms that contribute to the development of resistance to the anti-cancer medication sotorasib in lung cancer patients. The study found that tumor cells can become tolerant to the therapy without genetic mutations by manipulating the KRAS-sotorasib interaction network. However, long-term treatment can lead to genetic mutations that result in permanent resistance. The researchers also discovered that combining sotorasib with the FDA-approved anti-cancer therapy carfilzomib can address medication resistance in lung cancer cells. These findings provide insights into the complex interplay between genetic and nongenetic mechanisms in therapy resistance and offer potential therapeutic strategies for managing lung cancer patients.